The system will be released at the American Association of Cancer Research Annual Interacting with in Washington, D.C., 18-21 April. This approach contrasts with the pixelated crystal technology found in most current Family pet and SPECT systems today. ‘Albira gives unprecedented sensitivity and quality allowing researchers to visualize metabolic procedures and structures in small living animals. It’s the technology into the future made reality now,’ stated J.Thomas Zeller, Mind of the Angiology Department, Heart Middle Bad-Krozingen. Prof. I welcome the release of the 5X300 mm. ‘We are focused on introducing services to the market continually, addressing the growing range of endovascular solutions,’ stated Lihu Avitov, Angioslide CEO. ‘With patients’ needs in mind, the 5X300 mm device is the first in a series of long balloons, increasing our current providing of 20-100 mm devices. The PROTEUS product family members provides additional self-confidence to clinicians treating their endovascular patients.’ The PROTEUS 5X300 mm is certainly released for the European market only presently, and is undergoing an evaluation regulatory process with the FDA.
BioCryst completes planned interim evaluation of peramivir Phase 3 trial for serious influenza BioCryst Pharmaceuticals, Inc.